



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

July 26, 2024

John Sperzel
Chief Executive Officer
T2 Biosystems, Inc.
101 Hartwell Ave.
Lexington, MA 02421

Re: T2 Biosystems, Inc.
Registration Statement on Form S-3
Filed July 19, 2024
File No. 333-280922

Dear John Sperzel:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Benjamin Richie at 202-551-7857 with any questions.

Sincerely,

Division of Corporation Finance
Office of Industrial Applications and
Services

cc: Evan G. Smith